Content about CDATA

March 26, 2014

Although observers have been arguing for many years that conflicts of interest in medical research hurt patient care and diminish research integrity, the issue has lately become particularly salient to policy makers, researchers, institutions, and other stakeholders. The result is an environment with increased suspicion about the relationships between industry, research institutions, and physicians and greater regulation of these relationships.

Although observers have been arguing for many years that conflicts of interest in medical research hurt patient care and diminish research integrity, the issue has lately become particularly salient to policy makers, researchers, institutions, and other stakeholders. The result is an environment with increased suspicion about the relationships between industry, research institutions, and physicians and greater regulation of these relationships.

March 26, 2014

Patient requests for access to drugs and biologics prior to their approval has long created a dilemma for biotechnology companies. This document provides "Points to Consider" for biotechnology companies confronting these issues.

Patient requests for access to drugs and biologics prior to their approval has long created a dilemma for biotechnology companies. This document provides "Points to Consider" for biotechnology companies confronting these issues.

Read the document (183 KB PDF)

March 11, 2014

We are the world’s largest biotechnology trade association providing advocacy, business development, and communications services for more than 1,000 members around the world.

We champion biotechnology and advocate for our members – both large and small.

We represent companies at all stages of development, from start-ups to Fortune 500s.

Members focus on:

March 11, 2014

Our members are integral in the development of our advocacy efforts, and this takes shape in the form of staff-level committees. Through these committees, our members have a seat at the table to effectively influence our policy development and public outreach.

Areas of focus include:

February 21, 2014

BIO's Fact Sheet pm tje 2-14 ISAAA Report.

SUMMARY

Millions of farmers around the world continue to choose to plant and replant genetically modified (GM) crop varieties because of their environmental and socio-economic benefits and the important role they play in maintaining food security, according to a new study.

January 30, 2014

Fact sheet on the impact of the 2014 RVO proposal on the environment.

Background

December 13, 2013

Position Title: Associate/Deputy General Counsel* for Agriculture & Environment

            (*Exact title will depend on seniority of individual hired for the position)

Department: Legal and Intellectual Property

Reports to: General Counsel & Head of Public Policy    

September 26, 2013

Position Title:            Assistant, Vaccines, Biodefense and Diagnostics Policy

Department:          Policy

September 24, 2013

California’s Assembly and Senate have both overwhelmingly passed Senate Bill 598, legislation that creates a pathway for the substitution of interchangeable biologic medicines.

California’s Assembly and Senate have both overwhelmingly passed Senate Bill 598, legislation that creates a pathway for the substitution of interchangeable biologic medicines.

Despite fierce opposition from insurance companies and large pharmacy chains, it is now on its way to the Governor’s desk. It’s critical for him to understand that this issue is one of the highest priorities for patients, healthcare providers and the life sciences industry.

September 11, 2013

 

Position Title:        Policy Coordinator

Department:           Industrial and Environmental

Reports to:              Executive Vice President

 

 

Responsibilities:    

 

August 28, 2013

Got questions? This page might have your answer. 

Q. Is there a cost to speak? 
A. This differs for each event. Generally, speakers in breakout sessions may be given complimentary registrations whereas all company presentations require registrations. There are discounted packages available. 

August 28, 2013

Increased Visibility = Increased Opportunity
Click to find out more

 

Increased Visibility = Increased Opportunity

BIO speakers represent the most thought-provoking, diverse talents from all corners of the industry – healthcare, to industrial and environmental, to finance and business development.

Benefits of speaking at a BIO event, where innovation and education come together, include:

August 21, 2013

BIO PAC serves as a non-partisan, transparent fund that provides financial support to candidates who demonstrate support on issues vital to our members and the biotechnology industry overall. BIO PAC provides BIO and its member companies the opportunity to strengthen relationships with candidates and a greater ability to communicate BIO priorities and messages.

August 21, 2013

YES!  I want to join BIO PAC and help advocate biotechnology.  I understand that my personal contribution is completely voluntary and will be used to support the campaigns of candidates for federal office.

August 21, 2013

YES! I want to support BIO PAC and help advocate biotechnology. BIO PAC financially supports candidates who understand our industry. I understand that my personal contribution is completely voluntary and will be used to support the campaigns of candidates for federal office.

August 15, 2013

Position Title:      Coordinator

Department:       State Government Relations and Alliance Development

Reports to:           Director, Alliance Development

 

Job Summary: 

 

August 9, 2013

Be a Thought Leader at an Upcoming BIO Event

BIO offers a plethora of speaking opportunities throughout the year all over the globe. Share your expertise in front of key decision makers in the biotechnology field. Select your BIO platform based upon your regional or industry expertise:

May 29, 2013

Position Title:       Manager, Event & Health Communications

Department:         Communications

Reports to::           Sr. Director, Health Communications and Director, Events Communications

Position summary: 

February 25, 2013

Recently BIO hosted the 15th annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. The conference is the largest investor conference focused on for established and emerging publicly traded and select private biotech companies.

BIO recently hosted the 15th annual BIO CEO & Investor Conference at the Waldorf Astoria New York, the largest investor conference focused on established and emerging publicly traded and select private biotech companies. This year’s event drew more than 1,200 industry leaders, welcomed over 750 investors and facilitated at least 1,300 One-on-One Partnering meetings. BIO’s successful portfolio of investor conferences includes the BIO Investor Forum taking place in San Francisco later this year.

February 1, 2013

The biosimilars pathway is critical for China's biotechnology industry – and this is evident in the investment the government is making in the manufacture of biotech products

January 17, 2013

BIO’s sponsorship opportunities provide industry leaders with heightened visibility through “Double Helix” and “Helix” sponsorships.

In molecular biology, the term double helix refers to the structure formed by double-stranded molecules of nucleic acids such as DNA and RNA. But here at BIO we know the term to also have a another meaning.

BIO recently launched a new sponsorship section on BIO.org that provides BIO’s Double Helix and Helix sponsors with a new information hub featuring upcoming branding and sponsorship opportunities, photos from past BIO events, and unique ways to get involved with BIO.

December 6, 2012

As an exclusive members-only benefit, BIO offers complimentary One-on-One meeting rooms during the JP Morgan Healthcare Conference, taking place January 7-10, 2013, in San Francisco.

JP Morgan Healthcare Conference

July 19, 2012

The PMDxWorking Group endeavors to foster a positive public policy environment that maximizes the potential impact of the personalized medicine industry for the benefit of patients.

The PMDxWorking Group endeavors to foster a positive public policy environment that maximizes the potential impact of the personalized medicine industry for the benefit of patients. With a focus on improving legislative, intellectual property,regulatory, and reimbursement frameworks, the PMDxWorking Group seeks to better align the incentives connecting the research, development and commercialization of personalized medicine products.